15 / 30
Page 87
conferenceseries
.com
Volume 7
Pharmaceutical Regulatory Affairs: Open Access
ISSN: 2167-7689
Pharma Europe 2018
May 07-09, 2018
May 07-09, 2018 | Frankfurt, Germany
15
th
Annual European Pharma Congress
Constructionof serum-resistance cationic polymer
α
-CD- PAMAMand evaluationof its performances
as gene delivery vector
Chen Jianhai
1
, Qin Linghao
1,2
, Cao Duanwen
1
and
Pan Shirong
3
1
Southern Medical University, China
2
Guangdong Pharmaceutical University, China
3
Sun Yat-sen University, China
P
olyamidoamine (PAMAM) dendrimers as synthetic gene vectors have been proved to be efficient gene delivery systems.
In this study, a kind of α-cyclodextrin-PAMAM conjugate polymer was synthesized as gene delivery vector. Based on
1H-NMR detection, about 6.4 PAMAM-G1 molecules were grafted onto an
α
-CD core. Agarose gel electrophoresis results
revealed that CyD-G1 could efficiently bind with DNA and condense them into nano-scale particles which showed similar
binding capacity of PEI-25K. Besides, it could protect DNA from DNase
Ⅰ
degradation in a low N/P ratio. When N/P ratio in
the CyD-G1/DNA polyplex was 40, the average particle size of CyD-G1/DNA polyplex was about 120nm, and zeta potential
was +21mv. Also, this polyplex could maintain its particle size in a serum-containing solution within 360 mins. In comparison
with PEI-25K carrier, CyD-G1 showed low cytotoxicity in various cell lines. Cell transfection results showed that CyD-G1
could efficiently deliver DNA into cells at N/P=80 compared with lipofectamine2000 and PEI-25K. Unlike lipofectamine2000
and PEI-25K, in serum-containing test condition, CyD-G1/DNA polyplex could maintain the transgene activities. The results
of confocal laser scanning microscopy indicated that most DNA entered into cell nuclei within 4h, and this phenomenon was
consistent with the results calculated by flow cytometry. Above all, CyD-G1 showed good transgene activities and this gene
delivery vector could be used not only for
in vitro
but also for
in vivo
testing.
jhchen06@126.comPharmaceut Reg Affairs 2018, Volume 7
DOI: 10.4172/2167-7689-C1-031